Free exposure report

Get report

Conflict-Affected and High-Risk Areas (CAHRA)

Regulatory and due diligence requirements for companies operating in or sourcing from regions characterized by armed conflict, fragile post-conflict conditions, or weak governance, focusing on preventing complicity in human rights abuses and international crimes through heightened human rights due diligence (HHRDD).

See current Conflict-Affected and High-Risk Areas (CAHRA) activity, then check whether the developments map to your products, sites, suppliers, markets, and internal owners.

Book a demo

Prefer to self-diagnose first? Get a free exposure assessment

Current activity

Steady

In line with the prior 8-week baseline

3-month trend

23 alerts tracked

Updated 18 June 2026, 17:47

Topic context

How to read CAHRA regulatory activity

What is CAHRA?

Regulatory and due diligence requirements for companies operating in or sourcing from regions characterized by armed conflict, fragile post-conflict conditions, or weak governance, focusing on preventing complicity in human rights abuses and international crimes through heightened human rights due diligence (HHRDD).

Why it matters

CAHRA developments can change product scope, supplier expectations, market access, reporting duties, and risk ownership. Foresight tracks the signals early so teams can respond before obligations become urgent.

How Foresight monitors it

Foresight monitors official sources, extracts structured regulatory intelligence, and maps alerts to a customer's products, substances, markets, and priorities so teams see the relevant signal with source evidence for review.

Frequently asked questions

Everything you need to know about Foresight's regulatory intelligence platform

Still have questions? Get in touch with our team

Join 3,500+ professionals staying ahead

Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.

Free forever. Unsubscribe anytime.

Read by professionals at

Boeing
AstraZeneca
Siemens
PepsiCo
SpaceX